237 related articles for article (PubMed ID: 37379135)
81. Ustekinumab as Induction and Maintenance Therapy for Crohn's Disease.
Feagan BG; Sandborn WJ; Gasink C; Jacobstein D; Lang Y; Friedman JR; Blank MA; Johanns J; Gao LL; Miao Y; Adedokun OJ; Sands BE; Hanauer SB; Vermeire S; Targan S; Ghosh S; de Villiers WJ; Colombel JF; Tulassay Z; Seidler U; Salzberg BA; Desreumaux P; Lee SD; Loftus EV; Dieleman LA; Katz S; Rutgeerts P;
N Engl J Med; 2016 Nov; 375(20):1946-1960. PubMed ID: 27959607
[TBL] [Abstract][Full Text] [Related]
82. Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
Sandborn WJ; Ghosh S; Panes J; Schreiber S; D'Haens G; Tanida S; Siffledeen J; Enejosa J; Zhou W; Othman AA; Huang B; Higgins PDR
Gastroenterology; 2020 Jun; 158(8):2139-2149.e14. PubMed ID: 32092309
[TBL] [Abstract][Full Text] [Related]
83. A SPECIAL MEETING REVIEW EDITION: Highlights in Inflammatory Bowel Disease From the 14th Congress of ECCO: A Review of Selected Presentations From the 14th Congress of the European Crohn's and Colitis Organisation (ECCO) • March 6-9, 2019 • Copenhagen, Denmark
Gastroenterol Hepatol (N Y); 2019 May; 15(5 Suppl 2):1-24. PubMed ID: 31632213
[No Abstract] [Full Text] [Related]
84. Curcumin-QingDai Combination for Patients With Active Ulcerative Colitis: A Randomized, Double-Blinded, Placebo-Controlled Trial.
Ben-Horin S; Salomon N; Karampekos G; Viazis N; Lahat A; Ungar B; Eliakim R; Kuperstein R; Kriger-Sharabi O; Reiss-Mintz H; Yanai H; Dotan I; Zittan E; Maharshak N; Hirsch A; Weitman M; Mantzaris GJ; Kopylov U
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):347-356.e6. PubMed ID: 37302449
[TBL] [Abstract][Full Text] [Related]
85. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
[TBL] [Abstract][Full Text] [Related]
86. Low dose naltrexone for induction of remission in Crohn's disease.
Parker CE; Nguyen TM; Segal D; MacDonald JK; Chande N
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD010410. PubMed ID: 29607497
[TBL] [Abstract][Full Text] [Related]
87. Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis.
Panaccione R; Danese S; Zhou W; Klaff J; Ilo D; Yao X; Levy G; Higgins PDR; Loftus EV; Chen S; Gonzalez YS; Leonard C; Hébuterne X; Lindsay JO; Cao Q; Nakase H; Colombel JF; Vermeire S
Aliment Pharmacol Ther; 2024 Feb; 59(3):393-408. PubMed ID: 38010661
[TBL] [Abstract][Full Text] [Related]
88. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
[TBL] [Abstract][Full Text] [Related]
89. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
[TBL] [Abstract][Full Text] [Related]
90. Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Lang A; Salomon N; Wu JC; Kopylov U; Lahat A; Har-Noy O; Ching JY; Cheong PK; Avidan B; Gamus D; Kaimakliotis I; Eliakim R; Ng SC; Ben-Horin S
Clin Gastroenterol Hepatol; 2015 Aug; 13(8):1444-9.e1. PubMed ID: 25724700
[TBL] [Abstract][Full Text] [Related]
91. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study.
Mayer L; Sandborn WJ; Stepanov Y; Geboes K; Hardi R; Yellin M; Tao X; Xu LA; Salter-Cid L; Gujrathi S; Aranda R; Luo AY
Gut; 2014 Mar; 63(3):442-50. PubMed ID: 23461895
[TBL] [Abstract][Full Text] [Related]
92. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.
Hyams J; Damaraju L; Blank M; Johanns J; Guzzo C; Winter HS; Kugathasan S; Cohen S; Markowitz J; Escher JC; Veereman-Wauters G; Crandall W; Baldassano R; Griffiths A;
Clin Gastroenterol Hepatol; 2012 Apr; 10(4):391-9.e1. PubMed ID: 22155755
[TBL] [Abstract][Full Text] [Related]
93. Modified-Release Phosphatidylcholine (LT-02) for Ulcerative Colitis: Two Double-Blind, Randomized, Placebo-Controlled Trials.
Dignass A; Stremmel W; Horyński M; Poyda O; Armerding P; Fellermann K; Langhorst J; Kuehbacher T; Uebel P; Stein J; Novacek G; Avalueva E; Oliinyk O; Hasselblatt P; Dorofeyev A; Heinemann H; Mueller R; Greinwald R; Reinisch W;
Clin Gastroenterol Hepatol; 2024 Apr; 22(4):810-820.e7. PubMed ID: 37806372
[TBL] [Abstract][Full Text] [Related]
94. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
[TBL] [Abstract][Full Text] [Related]
95. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Murray A; Nguyen TM; Parker CE; Feagan BG; MacDonald JK
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD000543. PubMed ID: 32786164
[TBL] [Abstract][Full Text] [Related]
96. Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis.
Dubinsky MC; Jairath V; Feagan BG; Naegeli AN; Tuttle J; Morris N; Shan M; Arora V; Lissoos T; Agada N; Hibi T; Sands BE
BMJ Open Gastroenterol; 2023 Mar; 10(1):. PubMed ID: 37001911
[TBL] [Abstract][Full Text] [Related]
97. ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension.
Vermeire S; Sands BE; Tilg H; Tulassay Z; Kempinski R; Danese S; Bunganič I; Nitcheu J; Santo J; Scherrer D; Biguenet S; Ehrlich HJ; Steens JM; Gineste P; Sandborn WJ
Lancet Gastroenterol Hepatol; 2022 Nov; 7(11):1024-1035. PubMed ID: 36075249
[TBL] [Abstract][Full Text] [Related]
98. Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Rubin DT; Cohen RD; Sandborn WJ; Lichtenstein GR; Axler J; Riddell RH; Zhu C; Barrett AC; Bortey E; Forbes WP
J Crohns Colitis; 2017 Jul; 11(7):785-791. PubMed ID: 28333362
[TBL] [Abstract][Full Text] [Related]
99. Azathioprine and 6-mercaptopurine for maintenance of surgically-induced remission in Crohn's disease.
Gordon M; Taylor K; Akobeng AK; Thomas AG
Cochrane Database Syst Rev; 2014 Aug; 2014(8):CD010233. PubMed ID: 25081347
[TBL] [Abstract][Full Text] [Related]
100. Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study.
Banerjee R; Pal P; Penmetsa A; Kathi P; Girish G; Goren I; Reddy DN
J Clin Gastroenterol; 2021 Sep; 55(8):702-708. PubMed ID: 32889959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
